ABSTRACT
Introduction Breast cancer (BC) is one of the most common cancers globally. Genetic testing can facilitate screening and risk-reducing recommendations, and inform use of targeted treatments. However, genes included in testing panels are from studies of European-ancestry participants. We sequenced Hispanic/Latina (H/L) women to identify BC susceptibility genes.
Methods We conducted a pooled BC case-control analysis in H/L women from the San Francisco Bay area, Los Angeles County, and Mexico (4,178 cases and 4,344 controls). Whole exome sequencing was conducted on 1,043 cases and 1,188 controls and a targeted 857-gene panel on the remaining samples. Using ancestry-adjusted SKAT-O analyses, we tested the association of loss of function (LoF) variants with overall, estrogen receptor (ER)-positive, and ER-negative BC risk. We calculated odds ratios (OR) for BC using ancestry-adjusted logistic regression models. We also tested the association of single variants with BC risk.
Results We saw a strong association of LoF variants in FANCM with ER-negative BC (p=4.1×10−7, OR [CI]: 6.7 [2.9-15.6]) and a nominal association with overall BC risk. Among known susceptibility genes, BRCA1 (p=2.3×10−10, OR [CI]: 24.9 [6.1-102.5]), BRCA2 (p=8.4×10−10, OR [CI]: 7.0 [3.5-14.0]), and PALB2 (p=1.8×10−8, OR [CI]: 6.5 [3.2-13.1]) were strongly associated with BC. There were nominally significant associations with CHEK2, RAD51D, and TP53.
Conclusion In H/L women, LoF variants in FANCM were strongly associated with ER-negative breast cancer risk. It previously was proposed as a possible susceptibility gene for ER-negative BC, but is not routinely tested in clinical practice. Our results demonstrate that FANCM should be added to BC gene panels.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the National Cancer Institute (R01CA184585, K24CA169004) and the State of California Initiative to Advance Precision Medicine (OPR18111). Research reported in this publication included work performed in the City of Hope Integrative Genomics Core supported by the National Cancer Institute of the National Institutes of Health under grant number P30CA033572. The content and views are solely the responsibility of the authors and should not be construed to represent the views of the National Institutes of Health. SLN and this research were partially funded by the Morris and Horowitz Families Professorship. The Multiethnic Cohort was supported by NIH grants R01CA164973, R01CA054281, and CA063464. Sequencing of the MEC controls was conducted as part of the Slim Initiative for Genomic Medicine, a project funded by the Carlos Slim Health Institute in Mexico. Seventy-six of the controls were from the California Teachers Study; the collection and data were funded through the National Institutes of Health (R01CA77398). The Northern California Breast Cancer Family Registry was supported by grant UM1 CA164920 from the National Cancer Institute. The SFBCS was funded by grants R01CA063446 and R01CA077305 from the National Cancer Institute, grant DAMD17-96-1-6071 from the US Department of Defense, and grant 7PB-0068 from the California Breast Cancer Research Program. The Kaiser Permanente Research Program on Genes, Environment and Health was supported by Kaiser Permanente national and regional Community Benefit programs, and grants from the Ellison Medical Foundation, the Wayne and Gladys Valley Foundation, and the Robert Wood Johnson Foundation. The PATHWAYS cohort was supported by grants from the National Cancer Institute (U01 CA195565 R01 CA105274) The CAMA Study was funded by Consejo Nacional de Ciencia y Tecnologıa, Mexico (SALUD-2002-C01-7462) and recruitment at the Puebla site was supported by R01CA120120. LF is supported by R01CA204797. JNW was supported by NIH RC4 CA153828; Breast Cancer Research Foundation (#20-172), and American Society of Clinical Oncology Conquer Cancer® Research Professorship in Breast Cancer Disparities. YS was supported by the National Center for Advancing Translational Sciences under award KL2TR001870 and the National Cancer Institute under award K08CA237829.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided informed consent prior to participation in each institution's approved IRB protocols. These IRBs include the University of California, San Francisco, City of Hope, University of Southern California, Instituto Nacional de Salud Pública in Cuernavaca, Mexico, Kaiser Permanente Northern California, Cancer Prevention Institute of California, and California Pacific Medical Center.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
